China · 
Who invested in Nurotron Biotechnology?
Nurotron Biotechnology's investors include Kleiner Perkins Caufield & Byers, Qiming Venture Partners, DT Capital Partners and KPCB Holdings.
20122013
?Round$16MSeries CChina · Series C startup
Who invested in Nurotron Biotechnology
2 rounds we have observed, with the 4 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$16Mraised across 2 rounds since 2011, from 2 sources
- Latest round
- Series C, $16MDec 2013
- Investors
- 4
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Round Sept 2011
- Biggest round
- $16M Series C · Dec 2013
- Between rounds
- 2.3 years from the last two
The rounds
- Dec 2013Series C$16M3 new
From a historical funding record
- Sept 2011
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
DT Capital PartnersVC firm1round
KPCB HoldingsInvestment firm1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about Nurotron Biotechnology
How much has Nurotron Biotechnology raised?
Nurotron Biotechnology has raised $16M across 2 rounds since 2011. One round did not disclose an amount, so the total is a floor.
When did Nurotron Biotechnology last raise?
Nurotron Biotechnology's most recent round was a Series C of $16M in Dec 2013.
What was Nurotron Biotechnology's biggest round?
Its most recent round, $16M in Dec 2013, is also its largest on record.
Who backed Nurotron Biotechnology first?
Nurotron Biotechnology's first round on record, in Sept 2011, was backed by Qiming Venture Partners.
What stage is Nurotron Biotechnology at?
Nurotron Biotechnology's latest named round is a Series C, in Dec 2013.
Where is Nurotron Biotechnology based?
Nurotron Biotechnology is based in China.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.